SRSai Sundar Rajan Raghavan

Sai Sundar Rajan Raghavan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sai Sundar Rajan Raghavan has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

    by Barnabas G. Williams, Jordan R. Barrett, Josefin Bartholdson Scott, Cassandra A. Rigby, Matteo Cagiada, Doris Quinkert, Kirsty McHugh, Anna Huhn, Sean A. Burnap, Camille Gourjault, et al.

  • Open Access

    Structural basis for synergistic antibody protection against the essential malaria invasion complex protein RIPR

    by Barnabas G Williams, Jordan R Barret, Josefin Bartholdson Scott, Cassandra A Rigby, Matteo Cagiada, Doris Quinkert, Kirsty McHugh, Anna Huhn, Sean A Burnap, Camille Gourjault, et al.

    Plasmodium falciparum RH5-interacting protein (RIPR) is the central component of the essential pentameric PTRAMP-CSS-RIPR-CyRPA-RH5 (PCRCR)-complex; a leading target of next-generation blood-stage malaria vaccines. However, the mechanisms whereby anti-RIPR antibodies inhibit malaria parasite invasion of erythrocytes are poorly understood. Here, we characterise 83 human IgG mAbs from RIPR-vaccinated Kymouse platform mice. Single mAbs have minimal neutralising activity, however, high-level synergistic growth inhibition is observed when using pools of mAbs targeting the flexible RIPR-Tail region. Structural characterisation and molecular dynamics simulations of the RIPR-Tail show that mAbs targeting EGF-like domains 6-8 (RIPR EGF (6-8) ), but not EGF-like domains 9-10 or the C-terminal domain (RIPR EGF (9-10)-CTD ), synergise to constrain the RIPR-Tail conformation. The same antibodies also dissociate PTRAMP-CSS from RIPR, thereby enabling anti-RIPR EGF (9-10)-CTD mAbs or anti-CSS single-domain antibodies to bind and potentiate the anti-RIPR EGF (6-8) IgG. Addition of these mAbs to IgG from humans immunised with the R78C (RIPR EGF (7-8) -CyRPA) candidate vaccine enhances malaria growth inhibition. These data provide a framework to guide design of next-generation blood-stage malaria vaccines.

  • Open Access

    Predicting the conformational flexibility of antibody and T cell receptor complementarity-determining regions

    by Fabian C. Spoendlin, Monica L. Fernández-Quintero, Sai S. R. Raghavan, Hannah L. Turner, Anant Gharpure, Johannes R. Loeffler, Wing K. Wong, Alexander Bujotzek, Guy Georges, Andrew B. Ward, et al.

    Many proteins are highly flexible and their ability to adapt their shape can be fundamental to their functional properties. For example, the flexibility of antibody complementarity-determining region (CDR) loops influences binding affinity and specificity, making it a key factor in understanding and designing antigen interactions. With methods such as AlphaFold, it is possible to computationally predict a single, static protein structure with high accuracy. However, the reliable prediction of structural flexibility has not yet been achieved. A major factor limiting such predictions is the scarcity of suitable training data. Here we focus on predicting the structural flexibility of functionally important antibody and T cell receptor CDR3 loops. To this end, we constructed ALL-conformations by extracting CDR3s and CDR3-like loop motifs from all structures deposited in the Protein Data Bank. This dataset comprises 1.2 million loop structures representing more than 100,000 unique sequences and captures all experimentally observed conformations of these motifs. Using this dataset, we develop ITsFlexible, a deep learning tool with graph neural network architecture. We trained the model to binary classify CDR loops as ‘rigid’ or ‘flexible’ from inputs of antibody structures. ITsFlexible outperforms all alternative approaches on our crystal structure datasets and successfully generalizes to molecular dynamics simulations. We also used ITsFlexible to predict the flexibility of three CDRH3 loops with no solved structures and experimentally determined their conformations using cryogenic electron microscopy.


  • Open Access

    Identification of broadly inhibitory anti-PfEMP1 antibodies by mass spectrometry sequencing of plasma IgG from a malaria-exposed child

    by Louise Turner, Teresa Nunez de Villavicencio Diaz, Sai Sundar Rajan Raghavan, Ikhlaq Hussain Kana, Eric Lyimo, Chelsea Reitzel, Christian W. Wang, Ewen Berube, Rasmus W. Jensen, Johannes R. Loeffler, et al.

    Plasmodium falciparum pathology is driven by the accumulation of parasite-infected erythrocytes in blood capillaries. This sequestration process is mediated by the parasite’s P. falciparum erythrocyte membrane protein 1 (PfEMP1) adhesins, which bind select endothelial cell receptors. A subset of PfEMP1 binding human endothelial protein C receptor (EPCR) through their cysteine-rich interdomain region alpha 1 (CIDRα1) domains drives the pathogenesis to severe malaria. Despite high sequence diversity among CIDRα1 domains, individuals living in malaria-endemic regions become immune to severe disease in part through acquisition of antibodies inhibiting the PfEMP1–EPCR interaction. Here, we demonstrate an approach to identify pathogen-specific human monoclonal antibodies from plasma, combining mass spectrometry analysis of antigen-purified polyclonal plasma IgG and Ig transcript sequencing. We identified a clonal family of broadly reactive and EPCR binding-inhibitory human monoclonal antibodies against CIDRα1. The antibodies, isolated from a 9-y-old child, exhibited potent inhibition of EPCR binding broadly across CIDRα1 domains as well as binding of infected erythrocytes to EPCR. Structural analysis of one antibody variant complexed with CIDRα1 revealed a shared epitope of the clonal antibody family overlapping the EPCR binding site and the epitopes of two previously identified monoclonal antibodies, C7 and C74, with similar functional patterns. However, although C7, C74, and 110-3 antibodies all depend on the same few residues conserved in CIDRα1 to retain EPCR binding, the 110-3 antibodies contact additional variable residues, reducing their breadth of reactivity across the CIDRα1 family. These data bolster the hypothesis that broadly inhibitory antibodies against severe malaria-associated PfEMP1 target similar epitopes and are commonly developed in malaria-exposed individuals.


  • Open Access

    Functional and epitope specific monoclonal antibody discovery directly from immune sera using cryo-EM

    by James A. Ferguson, Sai Sundar Rajan Raghavan, Garazi Peña Alzua, Disha Bhavsar, Jiachen Huang, Alesandra J. Rodriguez, Jonathan L. Torres, Maria Bottermann, Julianna Han, Florian Krammer, et al.

    Antibodies are crucial therapeutics, comprising a substantial portion of approved drugs due to their safety and clinical efficacy. Traditional antibody discovery methods are labor-intensive, limiting scalability and high-throughput analysis. Here, we improved upon our streamlined approach combining structural analysis and bioinformatics to infer heavy and light chain sequences from cryo-EM (cryo–electron microscopy) maps of serum-derived polyclonal antibodies (pAbs) bound to antigens. Using ModelAngelo, an automated structure-building tool, we accelerated pAb sequence determination and identified sequence matches in B cell repertoires via ModelAngelo-derived hidden Markov models (HMMs) associated with pAb structures. Benchmarking against results from a nonhuman primate HIV vaccine trial, our pipeline reduced analysis time from weeks to under a day with higher precision. Validation with murine immune sera from influenza vaccination revealed multiple protective antibodies. This workflow enhances antibody discovery, enabling faster, more accurate mapping of polyclonal responses with broad applications in vaccine development and therapeutic antibody discovery.


  • Open Access

    Predicting the conformational flexibility of antibody and T-cell receptor CDRs

    by Fabian C. Spoendlin, Monica L. Fernández-Quintero, Sai S. R. Raghavan, Hannah L. Turner, Anant Gharpure, Johannes R. Loeffler, Wing K. Wong, Alexander Bujotzek, Guy Georges, Andrew B. Ward, et al.

    : Many proteins are highly flexible and their ability to adapt their shape can be fundamental to their functional properties. We can now computationally predict a single, static protein structure with high accuracy. However, we are not yet able to reliably predict structural flexibility. A major factor limiting such predictions is the scarcity of suitable training data. Here, we focus on predicting the structural flexibility of the functionally important antibody and T-cell receptor CDR3 loops. We extracted a dataset of CDR3 like loop motifs from the PDB to create ALL-conformations, a dataset containing 1.2 million structures and more than 100,000 unique sequences. Using this dataset, we develop ITsFlexible a method classifying CDR3 flexibility, which outperforms all alternative approaches on our crystal structure datasets and successfully generalises to MD simulations. We also used ITsFlexible to predict the flexibility of three completely novel CDRH3 loops and experimentally determined their conformations using cryo-EM.


  • Open Access

    Functional and epitope specific monoclonal antibody discovery directly from immune sera using cryoEM

    by James A. Ferguson, Sai Sundar Rajan Raghavan, Garazi Peña Alzua, Disha Bhavsar, Jiachen Huang, Alesandra J. Rodriguez, Jonathan L. Torres, Maria Bottermann, Julianna Han, Florian Krammer, et al.

    Antibodies are crucial therapeutics, comprising a significant portion of approved drugs due to their safety and clinical efficacy. Traditional antibody discovery methods are labor-intensive, limiting scalability and high-throughput analysis. Here, we improved upon our streamlined approach combining structural analysis and bioinformatics to infer heavy and light chain sequences from electron potential maps of serum-derived polyclonal antibodies (pAbs) bound to antigens. Using ModelAngelo, an automated structure-building tool, we accelerated pAb sequence determination and identified sequence matches in B cell repertoires via ModelAngelo derived Hidden Markov Models (HMMs) associated with pAb structures. Benchmarking against results from a non-human primate HIV vaccine trial, our pipeline reduced analysis time from weeks to under a day with higher precision. Validation with murine immune sera from influenza vaccination revealed multiple protective antibodies. This workflow enhances antibody discovery, enabling faster, more accurate mapping of polyclonal responses with broad applications in vaccine development and therapeutic antibody discovery.


  • Broadly inhibitory antibodies to severe malaria virulence proteins

    by Raphael A. Reyes, Sai Sundar Rajan Raghavan, Nicholas K. Hurlburt, Viola Introini, Sebastiaan Bol, Ikhlaq Hussain Kana, Rasmus W. Jensen, Elizabeth Martinez-Scholze, María Gestal-Mato, Borja López-Gutiérrez, et al.

    Malaria pathology is driven by the accumulation of Plasmodium falciparum-infected erythrocytes in microvessels1. This process is mediated by the polymorphic erythrocyte membrane protein 1 (PfEMP1) adhesion proteins of the parasite. A subset of PfEMP1 variants that bind to human endothelial protein C receptor (EPCR) through their CIDRα1 domains is responsible for severe malaria pathogenesis2. A longstanding question is whether individual antibodies can recognize the large repertoire of circulating PfEMP1 variants. Here we describe two broadly reactive and inhibitory human monoclonal antibodies to CIDRα1. The antibodies isolated from two different individuals exhibited similar and consistent EPCR-binding inhibition of diverse CIDRα1 domains, representing five of the six subclasses of CIDRα1. Both antibodies inhibited EPCR binding of both recombinant full-length and native PfEMP1 proteins, as well as parasite sequestration in bioengineered 3D human brain microvessels under physiologically relevant flow conditions. Structural analyses of the two antibodies in complex with three different CIDRα1 antigen variants reveal similar binding mechanisms that depend on interactions with three highly conserved amino acid residues of the EPCR-binding site in CIDRα1. These broadly reactive antibodies are likely to represent a common mechanism of acquired immunity to severe malaria and offer novel insights for the design of a vaccine or treatment targeting severe malaria.


  • Open Access

    Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages

    by Melanie R. Walker, Alexander Underwood, Kasper H. Björnsson, Sai Sundar Rajan Raghavan, Maria R. Bassi, Alekxander Binderup, Long V. Pham, Santseharay Ramirez, Mette Pinholt, Robert Dagil, et al.

    The continuous emergence of SARS-CoV-2 variants of concern has rendered many therapeutic monoclonal antibodies (mAbs) ineffective. To date, there are no clinically authorized therapeutic antibodies effective against the recently circulating Omicron sub-lineages BA.2.86 and JN.1. Here, we report the isolation of broad and potent neutralizing human mAbs (HuMabs) from a healthcare worker infected with SARS-CoV-2 early in the pandemic. These include a genetically unique HuMab, named K501SP6, which can neutralize different Omicron sub-lineages, including BQ.1, XBB.1, BA.2.86 and JN.1, by targeting a highly conserved epitope on the N terminal domain, as well as an RBD-specific HuMab (K501SP3) with high potency towards earlier circulating variants that was escaped by the more recent Omicron sub-lineages through spike F486 and E484 substitutions. Characterizing SARS-CoV-2 spike-specific HuMabs, including broadly reactive non-RBD-specific HuMabs, can give insight into the immune mechanisms involved in neutralization and immune evasion, which can be a valuable addition to already existing SARS-CoV-2 therapies.


  • Open Access

    Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate

    by Elena Ethel Vidal-Calvo, Anne Martin-Salazar, Swati Choudhary, Robert Dagil, Sai Sundar Rajan Raghavan, Lara Duvnjak, Mie Anemone Nordmaj, Thomas Mandel Clausen, Ann Skafte, Jan Oberkofler, et al.

    Molecular similarities between embryonic and malignant cells can be exploited to target tumors through specific signatures absent in healthy adult tissues. One such embryonic signature tumors express is oncofetal chondroitin sulfate (ofCS), which supports disease progression and dissemination in cancer. Here, we report the identification and characterization of phage display-derived antibody fragments recognizing two distinct ofCS epitopes. These antibody fragments show binding affinity to ofCS in the low nanomolar range across a broad selection of solid tumor types in vitro and in vivo with minimal binding to normal, inflamed, or benign tumor tissues. Anti-ofCS antibody drug conjugates and bispecific immune cell engagers based on these targeting moieties disrupt tumor progression in animal models of human and murine cancers. Thus, anti-ofCS antibody fragments hold promise for the development of broadly effective therapeutic and diagnostic applications targeting human malignancies.